Clinical trial
ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX
NCT03417245 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 1, 2018
- Completion date
- July 14, 2021
- Enrollment
- 120 (actual)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.